{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 42,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/10",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.389,
        "w": 0.286,
        "x": 0.659,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Early Intervention with APX3330 can potentially slow the progression of Non-Proliferative Diabetic Retinopathy to Proliferative Diabetic Retinopathy",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a09366ca-cb8e-4219-a3bb-007a5fd53da7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.51,
        "w": 0.686,
        "x": 0.06,
        "y": 0.299
      },
      "kind": "chart",
      "text": "Percentage of Eyes that Worsen to PDR 100% 80% 60% 40% 20% 0% Mild NPDR (35) Moderate NPDR (43) Moderately Severe NPDR (47) Severe NPDR (53) DR Severity (DRSS Score) 5 Year Follow-up 3 Year Follow-up 1 Year Follow-up",
      "attrs": {
        "chart_type": "stacked bar"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5830e50-4e7b-4a36-83f9-16cea1f469f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.08,
        "x": 0.025,
        "y": 0.938
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df2ac0a3-de71-48c0-b807-ce0253f527de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.456,
        "x": 0.142,
        "y": 0.204
      },
      "kind": "paragraph",
      "text": "Regardless of severity, all eyes worsen over time",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1417772a-1605-4c2d-8d83-03cd40e6f945",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.806,
        "x": 0.118,
        "y": 0.883
      },
      "kind": "source-note",
      "text": "Spherix Global Insights: DR Market DYNAMIX October 2022 Early treatment diabetic retinopathy study research group. ophthalmology. 1991;98(5 suppl):823-33. Diabetes control and complications trial research group. N Engl J Med. 1993;329(14):997-86. Fathy C, Patel S, Sternberg P Jr, Kohanim S. Disparities in adherence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions. Semin Ophthalmol. 2016;31(4):364-377. doi: 10.3109/08820538.2016.1154170",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c88fffe-534e-4073-8461-232b2503d49a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.739,
        "x": 0.048,
        "y": 0.098
      },
      "kind": "title",
      "text": "NPDR Patients are Rarely Treated with anti-VEGF Intravitreal Injections Due to Treatment Burden",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83bd863d-ee49-4460-b05f-d00a226ae15e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.66,
        "x": 0.048,
        "y": 0.06
      },
      "kind": "title",
      "text": "Progression of DR Severity Measured up to 5 Years",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d439146-f472-4cb0-8b8e-c6f8e1058a4a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "102a927b-90d9-4296-a592-fca699191176",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Slides 6-10 describe the Diabetic Retinopathy market and unmet need",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}